BMO Capital analyst Evan Seigerman upgraded Replimune (REPL) to Market Perform from Underperform with a price target of $11, up from $2. The firm ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback